Anheuser-Busch Won’t Fund Controversial NIH Alcohol Study

The company’s announcement comes weeks after enrollment was suspended.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Large building with ISTOCK, DEBRAMILLETUpdate (June 18): STAT News reports that NIH has shut down the alcohol study. Lawrence Tabak, the head of a task force charged with examining the study, says, “the nature of the engagement with industry representatives calls into question the impartiality of the process.”

Anheuser-Busch InBev has withdrawn a $15-million funding commitment for a mammoth National Institutes of Health study on the effects of moderate alcohol consumption, The New York Times reports. The company’s announcement, made on Friday (June 8), comes after the planned study drew scrutiny over potential conflicts of interest on the part of NIH, which had courted corporate sponsors with the prospect of producing evidence of health benefits of regular drinking.

The planned $100-million study, administered by the NIH’s National Institute of Alcohol Abuse and Alcoholism (NIAAA) would assign thousands of participants either to have an alcoholic drink every day or abstain, and track their health outcomes and mortality over six years. The New York Times reported in March that in an effort to get beverage ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Shawna Williams

    Shawna was an editor at The Scientist from 2017 through 2022. She holds a bachelor's degree in biochemistry from Colorado College and a graduate certificate and science communication from the University of California, Santa Cruz.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo